Airway Smooth Muscle Hypertrophy and Hyperplasia in Asthma

Carregando...
Imagem de Miniatura
Citações na Scopus
234
Tipo de produção
article
Data de publicação
2012
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER THORACIC SOC
Autores
JAMES, Alan L.
ELLIOT, John G.
JONES, Robyn L.
CARROLL, Mark L.
BAI, Tony R.
ABRAMSON, Michael J.
MCKAY, Karen O.
GREEN, Francis H.
Citação
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, v.185, n.10, p.1058-1064, 2012
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Rationale: Increased thickness of the airway smooth muscle (ASM) layer in asthma may result from hyperplasia or hypertrophy of muscle cells or increased extracellular matrix (ECM). Objectives: To relate ASM hypertrophy, ASM hyperplasia, and deposition of ECM to the severity and duration of asthma. Methods: Airways from control subjects (n = 51) and from cases of nonfatal (n = 49) and fatal (n = 55) asthma were examined postmortem. Mean ASM cell volume (V-c), the number of ASM cells per length of airway (N-L), and the volume fraction of extracellular matrix (f(ECM)) within the ASM layer were estimated. Comparisons between subject groups were made on the basis of general linear regression models. Measurements and Main Results: Mean Vc was increased in the large airways of cases of nonfatal asthma (P = 0.015) and fatal asthma (P < 0.001) compared with control subjects. N-L was similar in nonfatal cases and control subjects but increased in large (P < 0.001), medium (P < 0.001), and small (P = 0.034) airways of cases of fatal asthma compared with control subjects and with nonfatal cases (large and medium airways, P <= 0.003). The f(ECM) was similar in cases of asthma and control subjects. Duration of asthma was associated with a small increase in N-L. Conclusions: Hypertrophy of ASM cells occurs in the large airways in both nonfatal and fatal cases of asthma, but hyperplasia of ASM cells is present in the large and small airways in fatal asthma cases only. Both are associated with an absolute increase in ECM. Duration of asthma has little or no effect on ASM hypertrophy or hyperplasia or f(ECM).
Palavras-chave
nonfatal asthma, extracellular matrix, asthma duration
Referências
  1. Abramson MJ, 2001, AM J RESP CRIT CARE, V163, P12
  2. Badri Kameswara Rao, 2008, Proc Am Thorac Soc, V5, P4, DOI 10.1513/pats.200704-049VS
  3. Bai TR, 2000, AM J RESP CRIT CARE, V162, P663
  4. BAI TR, 1991, AM REV RESPIR DIS, V143, P441
  5. Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487
  6. Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC
  7. Bentley J Kelley, 2008, Proc Am Thorac Soc, V5, P89, DOI 10.1513/pats.200705-063VS
  8. Bentley JK, 2009, AM J PHYSIOL-LUNG C, V296, pL176, DOI 10.1152/ajplung.90376.2008
  9. Black JL, 2001, AM J RESP CRIT CARE, V164, pS63
  10. CARROLL N, 1993, AM REV RESPIR DIS, V147, P405
  11. Dekkers Bart G J, 2009, Proc Am Thorac Soc, V6, P683, DOI 10.1513/pats.200907-056DP
  12. DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27
  13. EBINA M, 1990, AM REV RESPIR DIS, V141, P1327
  14. EBINA M, 1993, AM REV RESPIR DIS, V148, P720
  15. Goldsmith AM, 2006, AM J RESP CELL MOL, V34, P247, DOI 10.1165/rcmb.2005-0166OC
  16. Grainge CL, 2011, NEW ENGL J MED, V364, P2006, DOI 10.1056/NEJMoa1014350
  17. Green FHY, 2010, THORAX, V65, P32, DOI 10.1136/thx.2008.111435
  18. Hassan M, 2010, J ALLERGY CLIN IMMUN, V125, P1037, DOI 10.1016/j.jaci.2010.02.031
  19. Hassan M, 2010, J ALLERGY CLIN IMMUN, V125, pe1033
  20. HEARD BE, 1973, J PATHOL, V110, P319, DOI 10.1002/path.1711100406
  21. Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397
  22. Huber HL, 1922, ARCH INTERN MED, V30, P689
  23. James AL, 2009, EUR RESPIR J, V34, P1040, DOI 10.1183/09031936.00181608
  24. JAMES AL, 1989, AM REV RESPIR DIS, V139, P242
  25. James AL, 2008, J APPL PHYSIOL, V104, P1703, DOI 10.1152/japplphysiol.00169.2008
  26. James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC
  27. JAMES AL, 1988, AM REV RESPIR DIS, V138, P136
  28. Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474
  29. Knight DA, 2004, CURR OPIN PHARMACOL, V4, P251, DOI 10.1016/j.coph.2004.02.002
  30. KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220
  31. Ma XF, 1998, AM J PHYSIOL-CELL PH, V274, pC1206
  32. Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x
  33. Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC
  34. McKay KO, 2002, MED J AUSTRALIA, V177, pS45
  35. McParland BE, 2003, J APPL PHYSIOL, V95, P426, DOI 10.1152/japplphysiol.00159.2003
  36. MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171
  37. Oliver MN, 2007, AM J RESP CELL MOL, V37, P264, DOI 10.1165/rcmb.2006-04180C
  38. Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951
  39. Pohunek P, 2005, PEDIAT ALLERG IMM-UK, V16, P43, DOI 10.1111/j.1399-3038.2005.00239.x
  40. Regamey N, 2008, AM J RESP CRIT CARE, V177, P837, DOI 10.1164/rccm.200707-977OC
  41. Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC
  42. Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363
  43. Sparrow MP, 2003, RESP PHYSIOL NEUROBI, V137, P361, DOI 10.1016/S1569-9048(03)00159-9
  44. STERIO DC, 1984, J MICROSC-OXFORD, V134, P127
  45. TAKIZAWA T, 1971, AM REV RESPIR DIS, V104, P331
  46. Tillie-Leblond I, 2008, ALLERGY, V63, P533, DOI 10.1111/j.1398-9995.2008.01656.x
  47. Tough SC, 1996, J ASTHMA, V33, P179, DOI 10.3109/02770909609054550
  48. Ward JE, 2008, EUR RESPIR J, V32, P362, DOI [10.1183/09031936.00119307, 10.1183/0903193.00119307]
  49. Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC
  50. Xu KF, 2002, J APPL PHYSIOL, V93, P1833, DOI 10.1152/japplphysiol.00738.2001
  51. Zhou LM, 2004, AM J RESP CRIT CARE, V169, P703, DOI 10.1164/rccm.200307-964OC